Quantitating antibody uptake in vivo: Conditional dependence on antigen expression levels

Molecular Imaging and Biology

Volumn 13, Issue 4, 2011, Pages 623-632

  Thurber, Greg M ^a   Weissleder, Ralph ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Simches Research Building ^*  (United States)

Author keywords

Antibody localization; Antigen expression; Binding site barrier; Saturation; Tumor targeting

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY; FLUORESCENT DYE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIGEN BINDING; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VIVO STUDY; MATHEMATICAL MODEL; MICROMETASTASIS; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIBODIES, BLOCKING; ANTIGENS; FLUORESCENCE; HT29 CELLS; HUMANS; MICE; MODELS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052633316     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0397-7     Document Type: Article

References (44)

1. Li WP, Meyer LA, Capretto DA, Sherman CD, Anderson CJ (2008) Receptor-binding, biodistribution, and metabolism studies of Cu-64- DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm 23:158-171 (Pubitemid 351630188)
2. Zhao BS, Schwartz LH, Larson SM (2009) Imaging surrogates of tumor response to therapy: Anatomic and functional biomarkers. J Nucl Med 50:239-249
3. McLarty K, Cornelissen B, Cai ZL, Scollard DA, Costantini DL, Done SJ, Reilly RM (2009) Micro-SPECT/CT with In-111-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 50:1340-1348
4. Zhang YJ, Xiang LM, Hassan R, Pastan I (2007) Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci USA 104:17099-17104 (Pubitemid 350210998)
5. Wu AM, Senter PD (2005) Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146 (Pubitemid 41486395)
6. Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, Horak ID, Goldenberg DM (2005) Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 11:7109S-7121S (Pubitemid 41428712)
7. Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM (2008) Therapy of advanced B-lymphoma xenografts with a combination of Y-90-anti-CD22 IgG (Epratuzumab) and unlabeled Anti-CD20 IgG (Veltuzumab). Clin Cancer Res 14:6154-6160
8. Thurber G, Figueiredo J, Weissleder R (2009) Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model. Plos One 4:e8053
9. Zou P, Xu SB, Povoski SP, Wang A, Johnson MA, Martin EW, Subramaniam V, Xu R, Sun DX (2009) Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm 6:428-440
10. Urano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M, Nagano T, Watanabe T, Hasegawa A, Choyke PL et al (2009) Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 15:104-109
11. Rosenthal EL, Kulbersh BD, King T, Chaudhuri TR, Zinn KR (2007) Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther 6:1230-1238 (Pubitemid 46711986)
12. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G et al (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94:1484-1493 (Pubitemid 35251753)
13. Stollman TH, Scheer MGW, Franssen GM, Verrijp KN, Oyen WJG, Ruers TJM, Leenders WPJ, Boerman OC (2009) Tumor Accumulation of radiolabeled bevacizumab due to targeting of cell- and matrixassociated VEGF-A isoforms. Cancer Biother Radiopharm 24:195-200
14. Wu AM, Olafsen T (2008) Antibodies for molecular imaging of cancer. Cancer J 14:191-197
15. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM (2006) Early tumor response to Hsp90 therapy using HER2 PET: Comparison with F- 18-FDG PET. J Nucl Med 47:793-796 (Pubitemid 46768442)
16. Cai WB, Chen K, He LN, Cao QH, Koong A, Chen XY (2007) Quantitative PET of EGFR expression in xenograft-bearing mice using Cu-64-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34:850-858 (Pubitemid 46798960)
17. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM (2009) Associations between the uptake of In-111-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 36:81-93
18. Aerts H, Dubois L, Perk L, Vermaelen P, van Dongen G, Wouters BG, Lambin P (2009) Disparity between In vivo EGFR expression and Zr-89-labeled cetuximab uptake assessed with PET. J Nucl Med 50:123-131
19. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW (2008) Cetuximab: Preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 23:619-631
20. Niu G, Li Z, Xie J, Le Q-T, Chen X (2009) PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 50:1116-1123
21. Thurber G, Schmidt M, Wittrup KD (2008) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29:57-61
22. Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60:1421-1434
23. Thurber GM, Wittrup KD (2008) Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res 68:3334-3341
24. Thurber GM, Zajic SC, Wittrup KD (2007) Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 48:995-999 (Pubitemid 46909929)
25. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8:2861
26. Mager DE (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1-10 (Pubitemid 43795346)
27. Adams G, Schier R, McCall A, Simmons H, Horak E, Alpaugh K, Marks J, Weiner L (2001) High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 61:4750-4755 (Pubitemid 32691886)
28. Ackerman ME, Chalouni C, Schmidt MM, Raman VV, Ritter G, Old LJ, Mellman I, Wittrup KD (2008) A33 antigen displays persistent surface expression. Cancer Immunol Immunother 57:1017-1027
29. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H (1998) Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89:307-314 (Pubitemid 28197296)
30. Sharkey RM, Natale A, Goldenberg DM, Mattes MJ (1991) Rapid blood clearance of immunoglobulin-G2A and immunoglobulin-G2B in nude-mice. Cancer Res 51:3102-3107
31. Lonsmann H (1974) Interstitial fluid concentrations of albumin and immunoglobulin-G in normal men. Scand J Clin Lab Invest 34:119-122
32. Wiig H, Gyenge CC, Tenstad O (2005) The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J Physiol-London 567:557-567 (Pubitemid 41301051)
33. Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437:497-504 (Pubitemid 41613541)
34. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765-14770 (Pubitemid 26419043)
35. Maxwell JL, Terracio L, Borg TK, Baynes JW, Thorpe SR (1990) A fluorescent residualizing label for studies on protein-uptake and catabolism in vivo and in vitro. Biochem J 267:155-162 (Pubitemid 20122649)
36. Ferl GZ, Kenanova V, Wu AM, DiStefano JJ (2006) A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 5:1550-1558 (Pubitemid 44070492)
37. Sung C, Youle RJ, Dedrick RL (1990) Pharmacokinetic analysis of immunotoxin uptake in solid tumors-role of plasma kinetics, capillarypermeability, and binding. Cancer Res 50:7382-7392
38. Ahlstrom H, Christofferson R, Lorelius L (1988) Vascularization of the continuous human colonic cancer cell line LS 174 T deposited subcutaneously in nude rats. APMIS 96:701-710
39. Flynn A, Boxer G, Begent R, Pedley R (2001) Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images. Cancer Immunol Immunother 50:77-81 (Pubitemid 32424491)
40. Baxter L, Jain RK (1989) Transport of fluid and macromolecules in tumors: 1. Role of interstitial pressure and convection. Microvasc Res 37:77-104 (Pubitemid 19045527)
41. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM (2007) Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 179:2815-2823
42. Hilmas D, Gillette E (1974) Morphometric analyses of the microvasculature of tumors during growth and after X-irradiation. Cancer 33:103-110
43. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170(4):974-980, Mosby-Year Book Inc (Pubitemid 24157907)
44. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22:701-706 (Pubitemid 38702826)